Equities

OrganiGram Holdings Inc

OrganiGram Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)2.58
  • Today's Change0.02 / 0.78%
  • Shares traded534.08k
  • 1 Year change-6.52%
  • Beta1.0952
Data delayed at least 15 minutes, as of May 06 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CADIncome statement in CADView more

Year on year OrganiGram Holdings Inc's net income fell 1,640.54% from a loss of 14.28m to a larger loss of 248.60m despite revenues that grew 10.86% from 145.81m to 161.64m. An increase in the cost of goods sold as a percentage of sales from 105.78% to 119.17% was a component in the falling net income despite rising revenues.
Gross margin-21.04%
Net profit margin-174.24%
Operating margin-182.64%
Return on assets-61.84%
Return on equity-69.77%
Return on investment-68.43%
More ▼

Cash flow in CADView more

In 2023, cash reserves at OrganiGram Holdings Inc fell by 34.65m. However, Cash Flow from Investing totalled 4.94m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 38.78m for operations while cash used for financing totalled 817.00k.
Cash flow per share-3.04
Price/Cash flow per share--
Book value per share3.18
Tangible book value per share3.05
More ▼

Balance sheet in CADView more

OrganiGram Holdings Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio4.28
Quick ratio2.11
Total debt/total equity0.0005
Total debt/total capital0.0005
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.